


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

1. **(Currently Amended)** A compound of formula **I**:



I


wherein, independently for each occurrence,

L is a bond or L is alkyl, alkenyl, or cycloalkyl which may be substituted with one or more R₁;

A is a monocyclic ring of 4-7 atoms containing 0-2 heteroatoms, a bicyclic ring of 8-12 atoms containing 0-4 heteroatoms or a tricyclic ring of 12-16 atoms containing 0-6 heteroatoms wherein the rings are independently aliphatic, aromatic, heteroaryl, or heterocyclic; wherein the heteroatoms selected from N, S, and O, and wherein the rings are optionally substituted with one or more groups selected from C₁₋₄ alkyl, CH₂OH, OR'', SR'', CN, N(R'')₂, CH₂N(R'')₂, NO₂, CF₃, CO₂R'', CON(R'')₂, COR'', NR''C(O)R'', F, Cl, Br, I and -S(O)_tCF₃, wherein R'' is H, alkyl or alkaryl;

R₁ is, independently for each occurrence, H, alkyl, cycloalkyl, aryl, or alkaryl;

R₂ is



wherein, independently for each occurrence,

B is a bond, C(R₁)₂ or C=O;

~~E is O or S;~~

D is C(R₁)₂, NR₁, C=O,
 providing that the two Ds are different;

J is NR₁, CH₂, CH₂CH₂, or O;

~~M is CR₁ or N;~~

Q is N or CH;

~~U is O, H₂, or CH₂;~~

X is H, C₁₋₄ alkyl, CH₂OH, OR₁, SR₁, CN, N(R₁)₂, CH₂N(R₁)₂, NO₂, CF₃, CO₂R₁,

CON(R₁)₂, COR₁, NR₁C(O)R₁, F, Cl, Br, I, -S(O)_rCF₃,
 or

r is 0, 1, or 2;

~~R₆ is C(O)OR₁;~~


R₁ is as previously defined;

b is an integer from 0-4;

~~R₃ is alkyl or cycloalkyl; and~~

~~a is an integer from 0-4; and~~

~~Y₁ is~~



~~wherein,~~

~~R₄ is a water solubilizing group;~~

~~R₅ is H, alkyl, or cycloalkyl; and~~


~~n is an integer from 0 to 4;~~

or a pharmaceutically acceptable salt thereof.


2. **(Original)** The compound of claim 1, wherein L is a C₂ alkenyl.

3-4. **(Canceled)**

5. **(Original)** The compound of claim 1, wherein L is a C₂ alkenyl and R₂ is wherein R₁ is H.



6. **(Original)** The compound of claim 1, wherein L is a C₂ alkenyl and R₂ is wherein R₁ is H and the D adjacent to B is NR₁.



7-12. **(Canceled)**

13. **(Original)** The compound of claim 1, wherein A is a 9 membered bicyclic heteroaryl.

14. **(Original)** The compound of claim 1, wherein A comprises at least 1 heteroatom.

15-16. **(Canceled)**

17. **(Original)** The compound of claim 1, wherein A comprises at least 1 oxygen atom.

18.-23. **(Canceled)**

24. **(Original)** A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

25. **(Currently Amended)** The composition of claim 24, wherein the ~~composition~~ pharmaceutically acceptable carrier is suitable is formulated for intravenous or injectable, administration.

26.-30. **(Canceled)**

31. **(Currently Amended)** A tablet comprising the composition of claim 24, ~~The composition of claim 30, wherein the composition is formulated in tablets~~ such that the amount of compound provided in 20 tablets, if taken together, provides a dose of at least the ED₅₀ but no more than ten times the ED₅₀.
- 32.-33. **(Canceled)**
34. **(Currently Amended)** A pill for reducing bacterial levels in a subject with a bacteria related illness, comprising a compound of claim 53 4.
- 35.-48. **(Canceled)**
49. **(Original)** A kit comprising the pharmaceutical composition of claim 24 and instructions for use thereof.
50. **(Previously Presented)** The compound of claim 6, wherein B is CH₂.
51. **(Previously Presented)** The compound of claim 50, wherein A comprises a nine-membered bicyclic heteroaryl comprising at least one O.
52. **(Canceled)**
53. **(Previously Presented)** The compound (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)-N-methyl-N-(3-methyl-benzofuran-2-ylmethyl)acrylamide, or pharmaceutically acceptable salts thereof.
54. **(New)** A pharmaceutically acceptable composition comprising the compound of claim 53, and a pharmaceutically acceptable carrier.